Researchers at The University of Texas MD Anderson Cancer Center have confirmed a protein as an oncogene responsible for the most common and lethal form of pancreatic cancer known as pancreatic ductal adenocarcinoma (PDAC). ...
Sep 04, 2019
0
1113
Scientists have shown exactly how mutations in two different genes coordinate to drive the development of malignant lung tumors, according to a new report in the open-access journal eLife.
Aug 27, 2019
0
6
The vast majority of deadly lung cancer cases (85 percent) are termed non-small-cell lung carcinomas (NSCLCs), which often contain a mutated gene called LKB1. Salk Institute researchers have now discovered precisely why inactive ...
Jul 27, 2019
0
663
The Ivy Brain Tumor Center at the Barrow Neurological Institute, has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali) for the treatment of recurrent glioblastoma. The ...
Jul 25, 2019
0
8
A team of Florida State University researchers used a simple tumor model to show the importance of tissue microenvironment in primary tumor formation.
Apr 26, 2019
0
1
Scientists from the German Cancer Research Center found in a recent study that only three different genetic alterations drive the early development of malignant glioblastomas. At least one of these three cancer drivers was ...
Mar 21, 2019
0
128
A cellular identity switch protects a cancer-promoting genetic pathway from targeted therapy, researchers at The University of Texas MD Anderson Cancer Center today reported in Science Translational Medicine.
Mar 13, 2019
0
20
A study published in Nature Communications found that an inhibitor of an enzyme called ACVR1 slows tumor growth and increases survival in an animal model of diffuse intrinsic pontine glioma (DIPG) - the most deadly brain ...
Mar 04, 2019
0
7
Skin cancer is on the rise in the United States. Squamous cell carcinoma, the second most common form of cancer in the U.S., has the highest mortality rate of all non-melanoma skin cancers. In roughly two to five percent ...
Jan 14, 2019
0
1
In a phase three clinical trial, a drug called sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment, a significant increase in progression-free survival compared ...
Dec 19, 2018
0
13
